Dr. Jacobs is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1021 Morehead Medical Dr
Ste A
Charlotte, NC 28204Phone+1 980-442-2000Fax+1 704-355-5800
Summary
- Clinical Director, Division of Lymphoma Therapy & Research; Dept of Hematologic Oncology, BMT & Blood Disorders; Levine Cancer Institute/Atrium Health, Charlotte, NC
Dr. Jacobs joined the Levine Cancer Institute (LCI) in Charlotte, NC in 2015 where he has served as a CLL and lymphoma specialist since that time. He functions as a principle investigator on numerous clinical trials and now serves as the clinical director of the lymphoma division. Dr. Jacobs has both a clinical and research focus in patients with Chronic Lymphocytic Leukemia (CLL). In his role as a principal investigator, he oversees the clinical trials conducted at Levine Cancer Institute that involve the treatment of patients with CLL and lymphoma. Dr. Jacobs graduated from Baylor College of Medicine in Houston, TX in 2009. He then completed his internship and residency in internal medicine at Vanderbilt University in Nashville, TN in 2012. Dr. Jacobs returned to Houston and completed his training with his hematology/oncology fellowship at MD Anderson Cancer Center in 2015.
He has more than 20 publications and over 500 citings.
Education & Training
University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 2012 - 2015
Vanderbilt University Medical CenterResidency, Internal Medicine, 2009 - 2012
Baylor College of MedicineClass of 2009
Certifications & Licensure
NC State Medical License 2015 - 2025
TX State Medical License 2012 - 2017
TN State Medical License 2011 - 2012- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
Publications & Presentations
PubMed
- 73 citationsPrevalence and risk factors associated with development of ocular GVHD defined by NIH consensus criteria.Ryan Jacobs, U Tran, Heidi Chen, Adetola A. Kassim, Brian G. Engelhardt
Bone Marrow Transplantation. 2012-04-09 - 48 citationsCOVID-19 in patients with CLL: improved survival outcomes and update on management strategies.Lindsey E. Roeker, Toby A. Eyre, Meghan C. Thompson, Nicole Lamanna, Alexander Coltoff
Blood. 2021-07-23 - 236 citationsOutcomes of COVID-19 in patients with CLL: a multicenter international experience.Anthony R. Mato, Lindsey E. Roeker, Nicole Lamanna, John N. Allan, Lori A. Leslie
Blood. 2020-09-03
Press Mentions
Long Term Follow-up of Ibrutinib + Venetoclax as First-Line Treatment for Chronic Lymphocytic Leukemia (CLL) (CAPTIVATE Study)December 21st, 2022
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
